Literature DB >> 33355300

MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma.

Sathya Neelature Sriramareddy1, Keiran S M Smalley2,3.   

Abstract

Most uveal melanomas harbor mutations in Gαq and show constitutive MAPK activation. Although MEK inhibition has some efficacy against uveal melanoma, clinical responses are typically poor. The Gαq inhibitor-MEK inhibitor combination showed prolonged suppression of MAPK signaling in preclinical uveal melanoma models and led to improved therapeutic responses.See related article by Hitchman et al., p. 1476. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33355300      PMCID： PMC7925419          DOI： 10.1158/1078-0432.CCR-20-4530

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  5 in total

1.  HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Authors:  Fernanda Faião-Flores; Michael F Emmons; Michael A Durante; Fumi Kinose; Biswarup Saha; Bin Fang; John M Koomen; Srikumar P Chellappan; Silvya Stuchi Maria-Engler; Uwe Rix; Jonathan D Licht; J William Harbour; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

2.  Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Authors:  Richard D Carvajal; Sophie Piperno-Neumann; Ellen Kapiteijn; Paul B Chapman; Stephen Frank; Anthony M Joshua; Josep M Piulats; Pascal Wolter; Veronique Cocquyt; Bartosz Chmielowski; T R Jeffry Evans; Lauris Gastaud; Gerald Linette; Carola Berking; Jacob Schachter; Manuel J Rodrigues; Alexander N Shoushtari; Delyth Clemett; Dana Ghiorghiu; Gabriella Mariani; Shirley Spratt; Susan Lovick; Peter Barker; Elaine Kilgour; Zhongwu Lai; Gary K Schwartz; Paul Nathan
Journal:  J Clin Oncol       Date:  2018-03-12       Impact factor: 44.544

3.  Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Authors:  Caroline Robert; Jean J Grob; Daniil Stroyakovskiy; Boguslawa Karaszewska; Axel Hauschild; Evgeny Levchenko; Vanna Chiarion Sileni; Jacob Schachter; Claus Garbe; Igor Bondarenko; Helen Gogas; Mario Mandalá; John B A G Haanen; Celeste Lebbé; Andrzej Mackiewicz; Piotr Rutkowski; Paul D Nathan; Antoni Ribas; Michael A Davies; Keith T Flaherty; Paul Burgess; Monique Tan; Eduard Gasal; Maurizio Voi; Dirk Schadendorf; Georgina V Long
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

Review 4.  Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.

Authors:  Vivian Chua; Dominic Lapadula; Clinita Randolph; Jeffrey L Benovic; Philip B Wedegaertner; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2017-02-21       Impact factor: 5.852

5.  Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.

Authors:  Gabriella Bayshtok; Emilie Ceraudo; Tyler D Hitchman; Amanda R Moore; Cindy Lee; Ruobing Jia; Naitao Wang; Mohini R Pachai; Alexander N Shoushtari; Jasmine H Francis; Youxin Guan; Juliet Chen; Matthew T Chang; Barry S Taylor; Thomas P Sakmar; Thomas Huber; Ping Chi; Yu Chen
Journal:  Clin Cancer Res       Date:  2020-11-23       Impact factor: 13.801
  5 in total
  2 in total

Review 1.  GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma.

Authors:  Paula Silva-Rodríguez; Daniel Fernández-Díaz; Manuel Bande; María Pardo; Lourdes Loidi; María José Blanco-Teijeiro
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

2.  KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.

Authors:  Hongjun Zhang; Xiangnan Liu; Yong'an Chen; Rui Xu; Shengli He
Journal:  Biomed Res Int       Date:  2022-09-28       Impact factor: 3.246
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.